Insight Molecular Diagnostics (IMDX) Total Liabilities (2015 - 2026)

Insight Molecular Diagnostics (IMDX) has 12 years of Total Liabilities data on file, last reported at $51.1 million in Q1 2026.

• Quarterly Total Liabilities rose 1.95% year-over-year to $51.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $51.1 million (up 1.95% YoY) and the FY2025 annual result came in at $57.2 million, up 20.83% from the prior year.
• Total Liabilities retreated to $51.1 million in Q1 2026 per IMDX's latest filing, from $57.2 million in the prior quarter.
• The five-year high for Total Liabilities was $89.3 million in Q1 2022, with the low at $39.1 million in Q3 2023.
• Average Total Liabilities over 5 years is $55.9 million, with a median of $52.0 million recorded in 2024.
• Year-over-year, Total Liabilities jumped 293.82% in 2022 and plunged 55.95% in 2023.
• Insight Molecular Diagnostics' Total Liabilities stood at $60.5 million in 2022, then declined by 18.51% to $49.3 million in 2023, then decreased by 3.94% to $47.4 million in 2024, then advanced by 20.83% to $57.2 million in 2025, then declined by 10.66% to $51.1 million in 2026.
• Business Quant data shows IMDX's Total Liabilities at $51.1 million in Q1 2026, $57.2 million in Q4 2025, and $53.1 million in Q3 2025.